Skip to Content

Boston Scientific Corp BSX

Morningstar Rating
$67.24 +1.01 (1.53%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Boston Scientific Is Poised to Accelerate Its Atrial Fibrillation Ablation Business in 2024

Boston Scientific has solidified its footing as one of three major cardiac device makers and significantly improved its innovation and operational chops. Boston remains a tough competitor—even a prolonged period of operational and management upheaval from 2006 to 2014 wasn't enough to permanently impair the underlying business and Boston's ability to develop and commercialize new technology platforms. Under CEO Michael Mahoney, the firm has focused on introducing meaningful innovation and leveraging its historically formidable sales and marketing resources.

Price vs Fair Value

BSX is trading at a 10% premium.
Price
$67.34
Fair Value
$82.00
Uncertainty
Medium
1-Star Price
$32.24
5-Star Price
$62.30
Economic Moat
Vzgdhz
Capital Allocation
Gymzmkbg

Bulls Say, Bears Say

Bulls

Boston remains one of the top players when it comes to intellectual property in the medical technology arena, which bodes well for its ability to innovate enough to keep up with rivals.

Bears

Boston's coronary stent business is less moaty than its cardiac rhythm management segment.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BSX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$66.23
Day Range
$66.1667.43
52-Week Range
$47.5268.07
Bid/Ask
$67.17 / $67.69
Market Cap
$98.65 Bil
Volume/Avg
5.8 Mil / 6.4 Mil

Key Statistics

Price/Earnings (Normalized)
32.80
Price/Sales
6.91
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Growth
Total Number of Employees
48,000

Competitors

Valuation

Metric
BSX
EW
ABT
Price/Earnings (Normalized)
32.8036.9925.33
Price/Book Value
5.118.395.05
Price/Sales
6.919.424.90
Price/Cash Flow
30.0639.7920.20
Price/Earnings
BSX
EW
ABT

Financial Strength

Metric
BSX
EW
ABT
Quick Ratio
0.632.081.16
Current Ratio
1.323.381.64
Interest Coverage
8.4187.9810.86
Quick Ratio
BSX
EW
ABT

Profitability

Metric
BSX
EW
ABT
Return on Assets (Normalized)
8.92%17.13%10.63%
Return on Equity (Normalized)
16.33%24.32%20.87%
Return on Invested Capital (Normalized)
11.43%21.12%14.81%
Return on Assets
BSX
EW
ABT
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ABT
Abbott LaboratoriesShdwsv$195.1 Bil
SYK
Stryker CorpDstq$134.6 Bil
MDT
Medtronic PLCPpsmj$111.1 Bil
EW
Edwards Lifesciences CorpLwyjfk$55.8 Bil
DXCM
DexCom IncNgtw$51.9 Bil
ZBH
Zimmer Biomet Holdings IncJprwt$25.8 Bil
ALGN
Align Technology IncGxyzyy$23.8 Bil
PHG
Koninklijke Philips NV ADRYwzxcdp$19.1 Bil
PODD
Insulet CorpQfrflp$12.0 Bil

Sponsor Center